Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I/II trial of TG-4010 in combination with immune checkpoint inhibitors and chemotherapy in first line, stage IV non-small cell lung cancer patients with tumor cells expressing low or undetectable levels of PD-L1

Trial Profile

A phase I/II trial of TG-4010 in combination with immune checkpoint inhibitors and chemotherapy in first line, stage IV non-small cell lung cancer patients with tumor cells expressing low or undetectable levels of PD-L1

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 18 Dec 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TG 4010 (Primary) ; Immunomodulators
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Transgene
  • Most Recent Events

    • 12 Dec 2019 According to a Transgene media release, status changed from planning to withdrawn prior to enrolment, as company has taken the decision to stop further development of TG4010.
    • 20 Mar 2017 According to a Transgene media release, company is in prospective discussion with a pharma to conduct this trial and first patient expected to be enrolled towards the end of 2017 in this trial.
    • 05 Sep 2016 According to a Transgene media release, phase II trial is expected to be initiated in first half of 2017.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top